Deep Track Biotechnology Master Fund, Ltd.
SEC insider (Form 3/4/5 filer). CIK 0002015536. 10% Owner at Attovia Therapeutics, Inc. (ATTO) and 2 other issuers. 10 reported Form 4/5 transactions since Sep 2024; latest on Aug 6, 2026. Located in GEORGE TOWN.
Companies Deep Track Biotechnology Master Fund, Ltd. has filed insider reports for
- Attovia Therapeutics, Inc. (ATTO): 10% Owner
- LB PHARMACEUTICALS INC (LBRX): 10% Owner
- DYNAVAX TECHNOLOGIES CORP (DVAX): 10% Owner
Deep Track Biotechnology Master Fund, Ltd.
CIK: 0002015536
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
ConversionDirect2M shares- - Jul 30, 2026LBRX
LB PHARMACEUTICALS INC
PurchaseDirectPre-Funded Warrants (Right to Buy)
286.2K shares at avg. $34.94- - Feb 10, 2026DVAX
DYNAVAX TECHNOLOGIES CORP
Tender OfferDirect15.7M shares- - Feb 6, 2026LBRX
LB PHARMACEUTICALS INC
PurchaseIndirectPre-Funded Warrants (Right to Buy)
93.9K shares at avg. $21.17- - Feb 6, 2026LBRX
LB PHARMACEUTICALS INC
PurchaseDirectPre-Funded Warrants (Right to Buy)
378.4K shares at avg. $21.17- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
PurchaseIndirect666.7K shares at avg. $15.00$10.0M - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
ConversionDirect686.1K shares- - Sep 12, 2025LBRX
LB PHARMACEUTICALS INC
PurchaseDirect2M shares at avg. $15.00$30.0M - Aug 22, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
SaleDirect970.1K shares at avg. $10.59$10.3M - Aug 21, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
SaleDirect1.1M shares at avg. $11.03$12.1M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 6, 2026 |  ATTO Attovia Therapeutics, Inc. | Conversion | 1,957,138 | - | $0 | Direct |
| Jul 30, 2026 |  LBRX LB PHARMACEUTICALS INC | Purchase Pre-Funded Warrants (Right to Buy) | 286,205 | $34.94 | - | Direct |
| Feb 10, 2026 |  DVAX DYNAVAX TECHNOLOGIES CORP | Tender Offer | 15,726,349 | - | $0 | Direct |
| Feb 6, 2026 | LBRX LB PHARMACEUTICALS INC | Purchase Pre-Funded Warrants (Right to Buy) | 93,925 | $21.17 | - | Indirect |
| Feb 6, 2026 | LBRX LB PHARMACEUTICALS INC | Purchase Pre-Funded Warrants (Right to Buy) | 378,444 | $21.17 | - | Direct |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Purchase | 666,666 | $15.00 | $9,999,990 | Indirect |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Conversion | 686,138 | - | - | Direct |
| Sep 12, 2025 | LBRX LB PHARMACEUTICALS INC | Purchase | 2,000,000 | $15.00 | $30,000,000 | Direct |
| Aug 22, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | Sale | 970,143 | $10.59 | $10,273,814 | Direct |
| Aug 21, 2025 | DVAX DYNAVAX TECHNOLOGIES CORP | Sale | 1,094,994 | $11.03 | $12,077,784 | Direct |
1-10 of 10 transactions